Oral clodronate for adjuvant treatment of operable breast cancer: Results of a randomized, double-blind, placebo-controlled multicenter trial.

@article{Powles2004OralCF,
  title={Oral clodronate for adjuvant treatment of operable breast cancer: Results of a randomized, double-blind, placebo-controlled multicenter trial.},
  author={Trevor J. Powles and Alexander H. G. Paterson and Eugene V. McCloskey and Mika Kurkilahti and J. A. Kanis},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2004},
  volume={22 14_suppl},
  pages={528}
}
528 Background: The bisphosphonate clodronate (Bonefos) may reduce the incidence of bone metastases by inhibiting tumor-induced osteoclastic resorption of bone. METHODS This randomized, double-blind, placebo-controlled, multicenter trial evaluated the efficacy and safety of oral clodronate in 1,069 patients with primary operable stage I-III breast cancer from 1989-2000. Patients received oral clodronate (1600 mg/day) or placebo for 2 years, starting within 6 months of primary treatment… CONTINUE READING